表紙
市場調查報告書

美國的失眠症市場 ∼2021年:非藥物治療 (CBTI,催眠療法)/藥物治療 (處方藥,OTC)

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021

出版商 MarketsandMarkets 商品編碼 429375
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
美國的失眠症市場 ∼2021年:非藥物治療 (CBTI,催眠療法)/藥物治療 (處方藥,OTC) U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021
出版日期: 2017年01月25日內容資訊: 英文 144 Pages
簡介

美國的失眠症市場,2016年達33億8000萬美元,預計2021年達42億4000萬美元和,以4.6%的年複合成長率 (CAGR) 成長。非藥物治療 - CBTI (失眠症認知行為治療) 等 - 市場佔有率變大,另外近幾年廉價的OTC (一般用醫藥品)的銷售額急速擴大,不過,相應地處方藥 (品牌藥)的銷售額縮小。

本報告提供美國的失眠症治療的相關市場相關分析,疾病概要和市場基本結構,主要市場促進、阻礙因素,市場趨勢與今後的預測 (過去2年、今後6年份),各治療法 (非藥物治療/藥物治療)、各產品種類 (處方藥,OTC)的詳細趨勢,市場競爭的狀態,今後的技術開發、市場發展的方向性,主要企業簡介等調查、考察。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 簡介
  • 市場動態
    • 推動因素
      • 政府為了抑制失眠症相關的社會成本的輔助策略
      • OTC類的睡眠輔助劑,促進藥物治療市場成長
    • 阻礙因素
      • 學名藥的普及,品牌藥的銷售額減少
      • 苯重氮基鹽系/非苯重氮基鹽系醫藥品的副作用
      • 非藥物療法的存在,抑製藥物市場成長
    • 市場機會
      • 對更有效且安全的醫藥品的未滿足需求
      • 巨大的失眠症患者群的存在

第6章 非藥物治療的市場

  • 簡介
    • CBTI (失眠症認知行為治療)
    • 催眠療法
    • 其他替代療法
  • 各治療方法的推薦度 (%)
  • 定性的評估

第7章 藥物治療的市場

  • 簡介
  • 美國的失眠症藥物治療的市場規模:各類型
    • 處方藥市場
      • 各種類的分析
        • 非苯重氮基鹽系睡眠輔助劑
    • 一般用醫藥品 (OCT) 市場

第8章 競爭環境

  • 美國國內的主要企業
  • 主要的失眠症用行動應用程式
  • 美國的失眠症市場上主要企業策略
  • 競爭情形與趨勢
    • 產品的上市、認證
    • 產業合作、協定、產業聯盟
    • 企業收購

第9章 企業簡介

  • 簡介
  • MERCK & CO., INC.
  • Eisai
  • MEDA CONSUMER HEALTHCARE, INC
  • 武田藥品工業
  • PFIZER INC.
  • SANOFI
  • VANDA PHARMACEUTICALS
  • PERNIX THERAPEUTICS
  • PURDUE PHARMACEUTICALS L.P.

第10章 附錄

圖表一覽

目錄
Product Code: MD 4947

The U.S. insomnia market is projected to reach USD 4.24 billion by 2021 from USD 3.38 billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021.

In 2016, the cognitive behavioural therapy for insomnia (CBTI) segment is expected to account for the largest share of the market. The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.

In 2016, the prescription sleep aids segment is expected to account for the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market. In 2016, the zolpidem segment is expected to account for the largest share of the non-benzodaizepines prescription sleep aids market. However, higher adoption of generic products that are available are cheaper price is negatively affecting the growth of the market.

The over-the-counter sleep aids segment of the U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market include easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. In 2016, the antihistamines sleep aids segment is expected to hold the largest share of the over-the-counter sleep aids market, whereas, melatonin is expected to grow at the highest CAGR during the forecast period. Growing awareness about the advantages of melatonin such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.

Some of the key players offering insomnia treatment (pharmacological) include Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.).

The market study covers the U.S. insomnia market, by type of treatment, to estimate the overall market size during 2013 to 2021. This report also covers the drivers, restraints, and opportunities of the market along with the competitive landscape of the U.S. insomnia market players.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information regarding products and services offered by the top players in the U.S. insomnia market
  • Product Development/Innovation: Detailed insights on research & development activities, and new product launches in the U.S. insomnia market
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the U.S. insomnia market
  • Competitive Assessment: In-depth assessment of strategies, products, and pipeline products of the key players in the U.S. insomnia market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. KEY STAKEHOLDERS/INFLUENCERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION - NON-PHARMACOLOGICAL TREATMENTS MARKET
    • 2.1.1. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.1.2. KEY DATA FROM SECONDARY SOURCES
    • 2.1.3. KEY DATA FROM PRIMARY SOURCES
  • 2.2. MARKET SIZE ESTIMATION - PHARMACOLOGICAL TREATMENTS MARKET
    • 2.2.1. MARKET FORECAST MODEL
    • 2.2.2. MARKET SIZE ESTIMATION
    • 2.2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.4. KEY DATA FROM PRIMARY AND SECONDARY SOURCES
  • 2.3. RESEARCH ASSUMPTIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
  • 4.2. AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
  • 4.3. LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
  • 4.4. U.S. INSOMNIA MARKET: CONSUMER SELECTION CRITERIA

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. MARKET DRIVERS
      • 5.2.1.3. GOVERNMENT SUPPORT TO CONTROL RISING INSOMNIA COST
      • 5.2.1.4. OTC SLEEP AIDS TO DRIVE THE PHARMACOLOGICAL TREATMENT MARKET GROWTH
    • 5.2.2. MARKET RESTRAINTS
      • 5.2.2.1. EROSION IN BRANDED PRESCRIPTION SLEEP AID SALES DUE TO GROWING ADOPTION OF GENERICS
      • 5.2.2.2. SIDE EFFECTS OF BENZODIAZEPINE AND NON-BENZODIAZEPINE DRUGS
      • 5.2.2.3. NON PHARMACOLOGICAL THERAPIES TO RESTRICT THE GROWTH OF DRUGS MARKET
    • 5.2.3. MARKET OPPORTUNITIES
      • 5.2.3.1. UNMET NEED FOR MORE EFFECTIVE AND SAFE DRUGS
      • 5.2.3.2. PRESENCE OF LARGE INSOMNIA POPULATION POOL

6. NON-PHARMACOLOGICAL TREATMENT MARKET

  • 6.1. INTRODUCTION
    • 6.1.1. COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
    • 6.1.2. HYPNOTHERAPY
    • 6.1.3. OTHER ALTERNATIVE THERAPIES
  • 6.2. THERAPY RECOMMENDATION, 2015(%)
  • 6.3. QUALITATIVE ASSESSMENT

7. PHARMACOLOGICAL TREATMENT MARKET

  • 7.1. INTRODUCTION
  • 7.2. U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE, BY TYPE
    • 7.2.1. U.S.: PRESCRIPTION SLEEP AIDS MARKET SIZE FOR INSOMNIA
      • 7.2.1.1. U.S.: PRESCRIPTION SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
        • 7.2.1.1.1. U.S.: NON- BENZODIAZEPINE SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE
    • 7.2.2. U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE

8. COMPETITIVE LANDSCAPE

  • 8.1. KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET
  • 8.2. TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA
  • 8.3. CORPORATE STRATEGIES FOLLOWED WITHIN U.S. INSOMNIA MARKET
  • 8.4. COMPETITIVE SITUATIONS & TRENDS
    • 8.4.1. PRODUCT LAUNCHES & APPROVALS
    • 8.4.2. COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS
    • 8.4.3. ACQUISITIONS

9. COMPANY PROFILES

  • 9.1. INTRODUCTION
  • 9.2. MERCK & CO., INC.
  • 9.3. EISAI CO., LTD.
  • 9.4. MEDA CONSUMER HEALTHCARE, INC
  • 9.5. TAKEDA PHARMACEUTICALS COMPANY LTD.
  • 9.6. PFIZER INC.
  • 9.7. SANOFI
  • 9.8. VANDA PHARMACEUTICALS
  • 9.9. PERNIX THERAPEUTICS
  • 9.10. PURDUE PHARMACEUTICALS L.P.

10. APPENDIX

  • 10.1. DISCUSSION GUIDE
  • 10.2. RELATED REPORTS
  • 10.3. RELATED REPORTS
  • 10.4. KNOWLEDGESTORE SUBSCRIPTION PORTAL
  • 10.5. MNM KNOWLEDGESTORE: SNAPSHOT
  • 10.6. RT: REAL-TIME MARKET INTELLIGENCE
  • 10.7. DISCLAIMER
  • 10.8. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: KEY STAKEHOLDERS/INFLUENCERS FOR DIAGNOSED INSOMNIA PATIENTS
  • TABLE 2: PHYSICIANS VIEWS ABOUT COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA (CBTI)
  • TABLE 3: AGE-WISE COMMONLY USED/PRESCRIBED TREATMENTS FOR EACH TYPE OF INSOMNIA
  • TABLE 4: LIST OF ONGOING PHASE-III CLINICAL TRAILS FOR INSOMNIA
  • TABLE 5: INSOMNIA TREATMENT SELECTION CRITERIA: IMPACT ANALYSIS
  • TABLE 6: U.S. INSOMNIA MARKET, BY NON-PHARMACOLOGICAL TREATMENT (QUALITATIVE ASSESSMENT)
  • TABLE 7: U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 8: U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SIZE , BY PRESCRIPTION SLEEP AIDS, 2013-2021 (USD MILLION)
  • TABLE 9: U.S.: PRESCRIPTIONS SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 10: U.S.: NON- BENZODIAZEPINE SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 11: U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SIZE FOR INSOMNIA, BY TYPE, 2013-2021 (USD MILLION)
  • TABLE 12: KEY PLAYERS IN THE U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET (2016)
  • TABLE 13: TOP AVAILABLE MOBILE APPLICATIONS FOR INSOMNIA (2016)
  • TABLE 14: PRODUCT LAUNCHES AND APPROVALS, 2013 -2016
  • TABLE 15: COLLABORATIONS, AGREEMENTS AND PARTNERSHIPS 2013-2016
  • TABLE 16: ACQUISITIONS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: SEGMENTATION & COVERAGE
  • FIGURE 2: PREVALENCE OF INSOMNIA, BY TYPE (2012-2015)
  • FIGURE 3: RESEARCH DESIGN - NON-PHARMACOLOGICAL TREATMENTS MARKET
  • FIGURE 4: MARKET BREAKDOWN AND DATA TRIANGULATION - NON-PHARMACOLOGICAL TREATMENTS MARKET
  • FIGURE 5: FORECASTING MODEL- PHARMACOLOGICAL TREATMENTS MARKET
  • FIGURE 6: MARKET SIZE ESTIMATION - PHARMACOLOGICAL TREATMENTS MARKET
  • FIGURE 7: MARKET BREAKDOWN AND DATA TRIANGULATION - PHARMACOLOGICAL TREATMENTS MARKET
  • FIGURE 8: ASSUMPTIONS FOR THE STUDY
  • FIGURE 9: U.S. INSOMNIA MARKET SCOPE
  • FIGURE 10: PHARMACOLOGICAL TREATMENT MARKET SHARE, BY TYPE (2014-2021)
  • FIGURE 11: U.S. INSOMNIA MARKET: CONSUMER SELECTION CRITERIA
  • FIGURE 12: U.S. INSOMNIA MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 13: U.S. INSOMNIA MARKET, BY NON-PHARMACOLOGICAL TREATMENT, THERAPY RECOMMENDATION, 2015 (%)
  • FIGURE 14: U.S. INSOMNIA PHARMACOLOGICAL TREATMENT MARKET SEGMENTATION
  • FIGURE 15: U.S.: INSOMNIA PHARMACOLOGICAL TREATMENT MARKET, 2013-2021 (USD MILLION)
  • FIGURE 16: MARKET SHARE: PHARMACOLOGICAL TREATMENT MARKET (2016)
  • FIGURE 17: MARKET SHARE: PRESCRIPTION SLEEP AIDS MARKET (2016)
  • FIGURE 18: U.S. INSOMNIA PRESCRIPTION SLEEP AIDS MARKET SNAPSHOT
  • FIGURE 19: MARKET SHARE: NON-BENZODIAZEPINE SLEEP AIDS MARKET (2016)
  • FIGURE 20: MARKET SHARE: NON-BENZODIAZEPINE SLEEP AIDS MARKET (2016)
  • FIGURE 21: U.S.: OVER-THE-COUNTER (OTC) SLEEP AIDS MARKET SNAPSHOT
  • FIGURE 22: BATTLE FOR MARKET SHARE: PRODUCT LAUNCHES AND APPROVALS-KEY STRATEGIES ADOPTED BY MARKET PLAYERS (2013-2016)
  • FIGURE 23: GEOGRAPHIC REVENUE MIX OF MAJOR PLAYERS IN THE U.S. INSOMNIA MARKET (2016)
  • FIGURE 24: SUMITOMO DAINIPPON PHARMA CO., LTD.: COMPANY SNAPSHOT (2015)
  • FIGURE 25: SANOFI: COMPANY SNAPSHOT (2015)
  • FIGURE 26: PFIZER INC: COMPANY SNAPSHOT (2015)
  • FIGURE 27: TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT (2015)
  • FIGURE 28: MERCK & CO., INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 29: MEDA CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 30: EISAI CO., LTD.: COMPANY SNAPSHOT (2015)
  • FIGURE 31: PURDUE PHARMACEUTICALS L.P.: COMPANY SNAPSHOT (2015)
  • FIGURE 32: PERNIX THERAPEUTICS: COMPANY SNAPSHOT (2015)
  • FIGURE 33: VANDA PHARMACEUTICALS: COMPANY SNAPSHOT (2015)
Back to Top